Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 302

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

Open access
de Zeeuw, Dick, Coll, Blai, Andress, Dennis, Brennan, John J., Tang, Hui, Houser, Mark, Correa-Rotter, Ricardo, Kohan, Donald, Lambers Heerspink, Hiddo J., Makino, Hirofumi, Perkovic, Vlado, Pritchett, Yili, Remuzzi, Giuseppe, Tobe, Sheldon W., Toto, Robert, Viberti, Giancarlo, Parving, Hans-Henrik · 2014 · Journal of the American Society of Nephrology

Abstract

Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have high cardiorenal morbidity and mortality related to residual albuminuria. We evaluated whether or not atrasentan, a selective endothelin A receptor antagonist, further reduces albuminuria when administered concomitantly with maximum tolerated labeled doses of RAS inhibitors. We enrolled 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g, and eGFRs of 30-75 ml/min per 1.73 m(2) in two identically designed, parallel, multinational, double-blind studies. Participants were randomized to placebo (n=50) or to 0.75 mg/d (n=78) or 1.25 mg/d (n=83) atrasentan for 12 weeks. Compared with placebo, 0.75 mg and 1.25 mg atrasentan reduced urine albumin/creatinine ratios by an average of 35% and 38% (95% confidence intervals of 24 to 45 and 28 to 47, respectively) and reduced albuminuria≥30% in 51% and 55% of participants, respectively. eGFR and office BP measurements did not change, whereas 24-hour systolic and diastolic BP, LDL cholesterol, and triglyceride levels decreased significantly in both treatment groups. Use of atrasentan was associated with a significant increase in weight and a reduction in hemoglobin, but rates of peripheral edema, heart failure, or other side effects did not differ between groups. However, more patients treated with 1.25 mg/d atrasentan discontinued due to adverse events. After stopping atrasentan for 30 days, measured parameters returned to pretreatment levels. In conclusion, atrasentan reduced albuminuria and improved BP and lipid spectrum with manageable fluid overload-related adverse events in patients with type 2 diabetic nephropathy receiving RAS inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2013080830

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. de Zeeuw, 1995, Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome., J Hypertens Suppl, 13, S53, 10.1097/00004872-199507001-00008 · doi:10.1097/00004872-199507001-00008

Cited by

See all 302

Metadata

Authors
de Zeeuw, D., Coll, B., Andress, D., Brennan, J. J., Tang, H., Houser, M., Correa-Rotter, R., Kohan, D., Lambers Heerspink, H. J., Makino, H., Perkovic, V., Pritchett, Y., Remuzzi, G., Tobe, S. W., Toto, R., Viberti, G., & Parving, H.-H.
Venue
Journal of the American Society of Nephrology
Published
2014-05
Volume
25
Issue
5
Pages
1083-1093
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2096179755
Cited by
302
References
17
FWCI
22.10
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.